Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory Hodgkin's lymphoma.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alliance for Clinical Trials in Oncology
• Collaborator: National Cancer Institute (NCI)
• Treatments: Doxorubicin; Gemcitabine; Liposomal doxorubicin; Vinblastine; Vinorelbine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed Hodgkin's lymphoma that is recurrent or refractory after standard chemotherapy

• Core biopsy is acceptable if adequate tissue is obtained for primary diagnosis and immunophenotyping

• Bone marrow biopsy is not acceptable as sole means of diagnosis

• Measurable disease

• Tumor mass greater than 1 cm

PATIENT CHARACTERISTICS:

Age:

• Any age

Hematopoietic:

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

Hepatic:

• Bilirubin no greater than 2.0 mg/dL unless history of Gilbert's disease

• AST no greater than 2 times upper limit of normal

Renal:

• Creatinine no greater than 2.0 mg/dL

Cardiovascular:

• LVEF at least 45% by MUGA (for patients whose lifetime cumulative doxorubicin dose exceeds 400 mg/m^2)

Other:

• Not pregnant or nursing

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• No prior gemcitabine, vinorelbine, or doxorubicin HCl liposome

• No other concurrent chemotherapy

Endocrine therapy:

• No concurrent hormones except for nondisease-related conditions (e.g., insulin for diabetes) or steroids for adrenal failure

• No concurrent dexamethasone or other steroidal antiemetics